National Pharmacy Health & Leadership Alliance Verify a MemberMember Login
NPHLANational Pharmacy Health & Leadership Alliance
Apply for Membership

01MetabolicWhat Changed Today

What changed today in Metabolic: 9 trial updates

Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.

By NPHLA IntelligencePublished Last updated Automated from official records

The signal

NPHLA tracked 9 new official records on this desk today: 9 trial updates.

Why this matters

GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.

What changed

  1. New trial registered: GLP1-SARCO (GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes)[1]
  2. New trial registered: Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery[2]
  3. New trial registered: OFF-RAMP (Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s)[3]
  4. New trial registered: Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and…[4]
  5. New trial registered: Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher[5]
  6. New trial registered: WB-EMS (WB-EMS Combined With Nutritional Guidance for a High-Protein Diet on Body Composition, Muscle Function, Psychological…)[6]
  7. New trial registered: Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain[7]
  8. New trial registered: Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)[8]
  9. New trial registered: PIVOT (Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access)[9]
  10. Also reported by Pharmacy Times: “Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4”.[10]
  11. Also reported by Drug Topics: “Orforglipron Shows Greater A1C, Weight Reduction Than Oral Semaglutide”.[11]
  12. Also reported by Dermatology Times: “Balancing Speed of Onset, Durability, and Comorbidities in Psoriasis Therapy”.[12]

Who this affects

  • Weight-management clinics
  • Med spas
  • Pharmacists
  • Prescribers
  • Medical directors
  • Practice owners & operators

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

NPHLA takeaway

These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.

Source file

  1. [1]
  2. [2]
  3. [3]
  4. [4]
  5. [5]
  6. [6]
  7. [7]
  8. [8]
  9. [9]
  10. [10]
    Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4

    News reportingPharmacy TimesIndustry coverage — headline and link only

  11. [11]
    Orforglipron Shows Greater A1C, Weight Reduction Than Oral Semaglutide

    News reportingDrug TopicsIndustry coverage — headline and link only

  12. [12]
    Balancing Speed of Onset, Durability, and Comorbidities in Psoriasis Therapy

    News reportingDermatology TimesIndustry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.